Mcbk s.c. Iwona Czajkowska Anna Podrazka Szczepaniak — Clinical Trial Site

20 Registered trials

7 Currently recruiting

Organisation

Mcbk s.c. Iwona Czajkowska Anna Podrazka Szczepaniak

Location

Grodzisk Mazowiecki, Poland

Identifier

ORG-100043488

Address

Ul. Daleka 32, 05-825, Poland

Departments

Dermatology
Mazowieckie Centrum Badan Klinicznych s.c. I. Czajkowska, A. Podrazka-Szczepaniak
MCBK
MCBK S.C. Iwona Czajkowska Anna Podrażka -Szczepaniak
N/A
NA
Not applicable

Clinical trials at this site (20)

Search interface

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Chronic Spontaneous Urticaria 5 2026-04-20
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Hidradenitis Suppurativa // Prurigo Nodularis // Vitili 5 2025-09-03
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting

2025-522403-17-00 Nummular Dermatitis 5 2026-04-10
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally i… Recruiting

2024-519919-34-00 Plaque psoriasis 5 2025-08-18
A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis Recruiting

2024-519291-11-00 Psoriatic Arthritis 4 2025-07-25
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona… Recruiting

2024-517458-90-00 Chronic obstructive pulmonary disease (COPD) 5 2025-06-06
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu… Recruiting

2023-506460-14-00 Chronic kidney disease (CKD) and hypertension. 5 2025-05-07
A Study Evaluating BFB759 in Atopic Dermatitis Ended

2025-521624-30-00 Atopic dermatitis 4 2026-01-08
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended

2024-516609-22-00 Primary Sjögren’s Disease 5 2025-04-15
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended

2023-505478-14-00 Psoriatic Arthritis 5 2019-05-09
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth… Ended

2022-501017-31-00 Rheumatoid arthritis 5 2016-05-10
A trial to learn how well balcinrenone in combination with dapagliflozin works and how safe it is compared to dapagliflozin alone in adults … Ended

2023-509709-63-00 Chronic Kidney Disease and Albuminuria 4 2024-07-30
A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended

2023-503910-60-00 Rheumatoid arthritis 4 2024-03-05
"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended

2023-505543-39-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-02-12
Open-Label Extension (OLE) Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren’s Syndrome (pSS) Ended

2023-503915-14-00 Primary Sjögren's Syndrome 4 2023-11-15
Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGROLT) Ended

2023-509801-59-00 Alopecia areata 5 2020-07-09
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace… Ended

2022-503050-39-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 5 2019-11-12
A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv… Ended

2023-508955-37-00 Moderate to severe atopic dermatitis 5 2018-10-10